Stockreport

Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months [Yaho...

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF Once-daily ZORYVE cream was well tolerated with a safety profile consistent with that in older children and adults Atopic dermatitis impacts 1 million children under [Read more]